Arvinas, Inc.
ARVNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeArvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. With a market capitalization of $585.9M, it sits in small-cap territory. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Market Cap
$585.9M
Beta
1.76
P/E (TTM)
34.92
P/E (Fwd)
-2.95
EPS (TTM)
$0.26
EPS (Fwd)
$-3.08
ROE
1.6%
ROA
-1.0%
Cash
$567.9M
Total Debt
$8.0M
Free CF
-$94.5M
52W Change
19.9%
Annual Financials
Cash vs Debt
Where ARVN stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ARVN finished 7.57% below its 150-day moving average ($10.04) and 12.12% below its 200-day moving average ($10.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARVN overbought or oversold?
At the September 2, 2026 close, ARVN's RSI(14) was 57.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $567.9M in cash and $8.0M in debt, ARVN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$94.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 1.6% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $131.4M to $262.6M.
Arvinas, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, ARVN has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ARVN.